98. Eosinophilic gastrointestinal disease Clinical trials / Disease details

Clinical trials : 171 / Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141

15 trials found

diseases per page:

Showing 1 to 10 of 15 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05247866 (ClinicalTrials.gov)	March 2022	21/12/2021	Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis	Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis	Eosinophilic Esophagitis	Dietary Supplement: EoE food introduction-1st;Dietary Supplement: E0E food introduction-2nd;Dietary ...	Children's Hospital of Philadelphia	Regeneron Pharmaceuticals;Genzyme, a Sanofi Company	Not yet recruiting	6 Years	25 Years	All	30	Phase 4	United States
2	NCT03678545 (ClinicalTrials.gov)	May 14, 2021	6/8/2018	Dupilumab in Eosinophilic Gastritis	A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab( ...	Eosinophilic Gastritis;Eosinophilic Gastroenteritis	Drug: Dupilumab (blinded);Drug: Placebo (blinded);Drug: Dupilumab (open-label)	Children's Hospital Medical Center, Cincinnati	Regeneron Pharmaceuticals;National Institutes of Health (NIH)	Recruiting	12 Years	70 Years	All	40	Phase 2	United States
3	NCT04776694 (ClinicalTrials.gov)	March 29, 2021	25/2/2021	Compassionate Use of Dupilumab		Bullous Pemphigoid;Eosinophilic Esophagitis (EoE);Pediatric Asthma;Pediatric and Adolescent Chronic ...	Drug: Dupilumab	Regeneron Pharmaceuticals	NULL	Available						NULL
4	NCT04394351 (ClinicalTrials.gov)	September 1, 2020	7/5/2020	Study to Investigate the Efficacy and Safety of Dupilumabin Pediatric Patients With Active Eosinophi ...	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupil ...	Eosinophilic Esophagitis (EoE)	Drug: Dupilumab;Drug: Matching Placebo	Regeneron Pharmaceuticals	Sanofi	Active, not recruiting	1 Year	11 Years	All	102	Phase 3	United States;Canada
5	EUCTR2018-000844-25-DE (EUCTR)	21/10/2019	13/11/2018	A study to determine the efficacy and safety of dupilumabin Adult and Adolescent Patients with Eosin ...	A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumabin Adult and ...	Eosinophilic Esophagitis (EoE) MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eos ...	Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUP ...	Regeneron Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	290	Phase 3	United States;Portugal;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;German ...
6	EUCTR2018-000844-25-SE (EUCTR)	09/10/2019	15/11/2018	A study to determine the efficacy and safety of dupilumabin Adult and Adolescent Patients with Eosin ...	A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumabin Adult and ...	Eosinophilic Esophagitis (EoE) MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eos ...	Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUP ...	Regeneron Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	290	Phase 3	United States;Portugal;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;German ...
7	EUCTR2018-000844-25-GB (EUCTR)	12/07/2019	20/11/2018	A study to determine the efficacy and safety of dupilumabin Adult and Adolescent Patients with Eosin ...	A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumabin Adult and ...	Eosinophilic Esophagitis (EoE) MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eos ...	Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUP ...	Regeneron Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	290	Phase 3	United States;Portugal;Spain;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Australia;German ...
8	EUCTR2018-000844-25-PT (EUCTR)	08/07/2019	26/12/2018	A study to determine the efficacy and safety of dupilumabin Adult and Adolescent Patients with Eosin ...	A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumabin Adult and ...	Eosinophilic Esophagitis (EoE) MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eos ...	Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUP ...	Regeneron Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	425	Phase 3	United States;Portugal;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;Denmar ...
9	EUCTR2018-000844-25-NL (EUCTR)	03/07/2019	11/12/2018	A study to determine the efficacy and safety of dupilumabin Adult and Adolescent Patients with Eosin ...	A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumabin Adult and ...	Eosinophilic Esophagitis (EoE) MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eos ...	Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUP ...	Regeneron Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	290	Phase 3	United States;Portugal;Spain;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Australia;Nether ...
10	EUCTR2018-000844-25-BE (EUCTR)	14/06/2019	14/03/2019	A study to determine the efficacy and safety of dupilumabin Adult and Adolescent Patients with Eosin ...	A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumabin Adult and ...	Eosinophilic Esophagitis (EoE) MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eos ...	Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUP ...	Regeneron Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	290	Phase 3	Canada;United States;Portugal;Spain;Italy;Switzerland;United Kingdom;France;Belgium;Australia;German ...

First Previous1 2Next Last